Continuing Medical Education and the Marketing of Fentanyl for Breakthrough Pain: Marketing Messages in an Industry‐Funded CME Module on Breakthrough Pain-Reference-Cited by-同舟云学术

Continuing Medical Education and the Marketing of Fentanyl for Breakthrough Pain: Marketing Messages in an Industry‐Funded CME Module on Breakthrough Pain

Published:2019-03 Issue:1 Volume:11 Page:43-58
ISSN:1948-4682
Container-title:World Medical & Health Policy
language:en
Short-container-title:World Medical & Health Policy

Author:

Infeld Margaret,Bell Alicia,Marlin Clare,Waterhouse Stephanie,Uliassi Nicole,Fugh‐Berman Adriane^ORCID

Publisher

Wiley

Subject

Health Policy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/wmh3.290

Reference32 articles.

1. 2006 Pipeline Insight: Breakthrough Pain.Fast Acting Players Will Capture Majority Market Share[Online].http://marketreportfinder.com/report/healthcare_pharmaceuticals_biotechnology/pharmaceuticals/pipeline_insight_breakthrough_pain_fast_acting_players_will_capture_majority_market_sharec84_83_1b.html‐order. Accessed February 7 2016.

2. Anonymous.2010.Drug Company Leader Says End Industry Support of CME. Bioethics Forum [Online].https://www.thehastingscenter.org/drug‐company‐leader‐says‐end‐industry‐support‐of‐cme/. Accessed February 20 2019.

3. Assessment of the Trends in Medical Use and Misuse of Opioid Analgesics From 2004 to 2011;Atluri Sairam;Pain Physician,2014

4. A Risk Stratification Tool to Assess Commercial Influences on Continuing Medical Education;Barnes Barbara E.;The Journal of Continuing Education in the Health Professions,2007

5. The Impact of Drug Company Funding on the Content of Continuing Medical Education;Bowman Marjorie A;The Journal of Continuing Education in the Health Professions,1986

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CME: Is it Meeting the Mark?;The American Journal of Medicine;2023-07

2. Frustrations Part 2: Tales of Bureaucracy—Rule by Desks;An Insider’s Guide to Academic Medicine;2023

3. Continuing professional development in the last decade – A scoping review;Journal of Adult and Continuing Education;2022-12-21

4. Permissive regulation: A critical review of the regulatory history of buprenorphine formulations in Canada;International Journal of Drug Policy;2022-07

5. Author’s reply to McMahon;BMJ;2021-07-23